Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era

摘要: Chronic myeloid leukemia cells contain a BCR-ABL oncoprotein with an enhanced tyrosine kinase activity, which is considered to be the principal 'cause' of leukemia. Though precise mechanisms underlying leukemogenesis remains enigmatic, use imatinib inhibit dysregulated activity has proved remarkably successful in clinical practice. Imatinib was first small molecule developed and its success introduced current era molecularly targeted therapies for number other malignancies. In patients chronic leukaemia who develop resistance imatinib, Bcr-Abl signaling pathway often re-established. This led emergence alternative treatment strategies designed target leukemic cell are resistant imatinib.